Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04409639 · OUTCOME

Overall Survival (OS)

Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations · Source last updated 2026-07-21

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Study anticipated to be 60 months.

What was measured

Assessment of long-term efficacy

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denom Units Selected
Participants
description
Assessment of long-term efficacy
reporting Status
NOT_POSTED
time Frame
Study anticipated to be 60 months.
title
Overall Survival (OS)
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice